Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
FARESTON |
| Manufacturer |
|
GTx |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nonsteroidal antiestrogen. |
| Generic Name |
|
Toremifene (as citrate) 60mg; tabs. |
| Indications |
|
Metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. |
| Children |
|
Not applicable. |
| Adults |
|
60mg once daily. Continue until disease progression is observed. |
| Precautions |
|
History of thromboembolic disease: not recommended. Bone metastases; monitor for hypercalcemia during first weeks of treatment, discontinue if severe. Pre-existing endometrial hyperplasia; long-term therapy not recommended. Leukopenia, thrombocytopenia; obtain leukocyte and platelet counts. Monitor CBCs, calcium levels, liver function tests periodically. Pregnancy (Cat.D). Nursing mothers. |
| Interactions |
|
Caution with drugs that decrease renal calcium excretions (eg, thiazide diuretics). Monitor anticoagulants (eg, warfarin). Potentiated by CYP3A4 inhibitors (eg, ketoconazole, erythromycin, other macrolides). Antagonized by CYP3A4 inducers (eg, phenobarbital, phenytoin, carbamazepine). |
| Adverse Reactions |
|
Hot flashes, sweating, GI upset, vaginal discharge, dizziness, edema, vaginal bleeding; hypercalcemia, tumor flare, endometrial hyperplasia; rare: leukopenia, thrombocytopenia. |
| How Supplied |
|
Tabs—30, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
